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Gene Expression Time Course in the Human Skin
during Elicitation of Allergic Contact Dermatitis
Malene B. Pedersen1, Lone Skov2, Torkil Menne´2, Jeanne D. Johansen1 and Jørgen Olsen3
Genes involved in the inflammatory response resulting in allergic contact dermatitis (ACD) are only partly
known. In this study, we introduce the use of high-density oligonucleotide arrays for gene expression profiling
in human skin during the elicitation of ACD. Skin biopsies from normal and nickel-exposed skin were obtained
from seven nickel-allergic patients and five nonallergic controls at four different time points during elicitation
of eczema. Each gene expression profile was analyzed by hybridization to high-density oligonucleotide arrays.
Cluster analysis of 74 genes found to be differentially expressed in the patients over time revealed that the
patient samples may be categorized into two groups: an early time-point group (no clinical reaction) and a late
time-point group (clinical reaction). Bioinformatics analyses unraveled the potential involvement of signal
transducers and activator of transcription and small/mothers against decepentaplegic (SMAD) transcription
factors in the late time-point gene expression patterns. Concerning specific genes, the homeostatic chemokine
CCL19 was unexpectedly found to be highly expressed in cells scattered in the deep dermis of the late time-
point samples. Taken together, these findings suggest hitherto unknown roles of SMAD transcription factors
and of CCL19 in the elicitation phase of ACD.
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INTRODUCTION
Allergic contact dermatitis (ACD), both occupational and
nonoccupational, comprises a major health problem in the
industrial world. The disease is characterized by local
inflammation in the skin with particular involvement of the
hands, feet, and face (Veien, 2006). Contact sensitizers or
haptens are small molecules with a molecular weight of
o700 Da (Scheynius, 1998). Common sensitizing haptens
include metals, biocides/preservatives, fragrance chemicals,
and dyes.
ACD is a type IV hypersensitivity mediated by activated
allergen-specific T lymphocytes. ACD is the clinical mani-
festation and it is preceded by a sensitization phase, which is
clinically silent. Much has been learned about ACD from
studies using the rodent contact hypersensitivity (CHS)
models. During sensitization, dendritic cells (DCs) that have
taken up a hapten migrate to draining lymph nodes (LNs)
where they mature, express costimulatory molecules, and
present antigens to naı¨ve CCR7-positive T cells (for reviews
see Sebastiani et al. 2002; Wang et al., 2003; Sanchez-
Sanchez et al., 2006). The CCR7-positive DCs as well as the
naı¨ve CCR7-expressing T cells are attracted to the LNs by
homeostatic CCR7 ligands, chemokines CCL19 and CCL21,
which are constitutively expressed in the LNs (Sebastiani
et al., 2002; Ebert et al., 2005). When a sensitized person is
exposed to the hapten, specific T cells are recruited by
chemokines to the skin where the cells undergo extensive
proliferation (Rustemeyer et al., 2003). The activated T cells
subsequently produce and release high levels of cytokines,
thereby causing an inflammatory process leading to eczema.
Interferon-g is believed to be an important T-cell-derived
cytokine with an effector function during the elicitation of
ACD (Wang et al., 2003). Given the complexity of the
molecular mechanisms, studies of isolated genes are not,
however, sufficient to give the complete picture of the
pathogenesis of ACD. No human genome-wide gene expres-
sion analysis has yet been reported for the elicitation phase
and in this study, we therefore introduce the use of DNA
microarrays (Stoughton, 2005) into the investigation of gene
expression changes in the skin during the elicitation of ACD.
It was our purpose to provide first an overall insight into the
biological processes and regulating transcription factors in
the elicitation phase of ACD from bioinformatics analyses of
the genome-wide expression data. Secondly, it was our
purpose to identify new specific molecular details about the
disease process.
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RESULTS
Patch test results
In all eight nickel-allergic patients, an allergic reaction was
elicited in response to nickel exposure. The visible allergic
reaction appeared at the 48- and 96-hour time points. No
visible eczema was observed in any patient at time point 0
and 7 hours. None of the six nonallergic controls had any
visible reaction to the patch test with nickel sulfate. Skin
biopsies were obtained at all four time points from all
participating patients and controls.
Multivariate analysis reveals active biological processes during
elicitation of ACD
RNA was extracted from the skin biopsies and a genome-
wide gene expression analysis carried out using Affymetrix
HGU 133 Plus 2.0 arrays. A one-way analysis of variance
(ANOVA) was used to filter the dataset, resulting in a list of
678 probe sets reporting significantly different expression
between the different groups of samples. The filtered probe
sets were subjected to correspondence analysis (CA). CA
reduced the 678 dimensions of the filtered dataset into two
dimensions, retaining 82% of the variation present in the
original filtered dataset. Thus, as a result of the dimension
reduction, the first two axes catch up with the main variations
in the original data. Figure 1 shows the score plot with the
projections of each biopsy on the plane defined by the first
and second CA axes. All the control biopsies are projected
into one group located mainly in the upper left quadrant
(negative values on the x axis and positive values on the y
axis), whereas all patient biopsies are mainly distributed
towards the upper and lower right quadrants (positive values
on the x axis). The patient biopsies are further subdivided into
two groups with different projections on the score plot. Late
patient biopsies (48 and 96 hours) are projected to the far
upper right quadrant, whereas the early patient biopsies (0
and 7 hours) are projected onto the lower right quadrant
(negative values on the y axis and positive values on the x
axis). Thus, Figure 1 reveals that the first axis distinguishes the
skin from patients from the skin of control subjects, whereas
the second axis separates skin in the late phase of the
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Figure 1. CA score plot. Plot of CA scores for the first and second CA axes. The projections of samples from control subjects, early (0 and 7 hours) patient
samples and late (48 and 96 hours) patient samples are indicated by circles. A single late patient sample (P7_48.CEL) is projected together with the early patient
group. The genes corresponding to the probe sets that define the positive and negative directions of the CA axis were analyzed for overrepresentation of terms for
biological processes. Overrepresented Go IDs and terms (compared to the list of genes defining the other end of the same axis) are written in continuation of the
axes.
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elicitation of ACD from skin in the early phase of the
elicitation of ACD.
The CA analysis was combined with a functional
annotation analysis. The principle behind this analysis
(Csillag et al., 2007a) is to identify the probe sets that define
the positive or negative directions of the axes and then
identify annotation terms that are significantly overrepre-
sented. The annotation terms are terms for biological
processes defined by the Gene Ontology Consortium
(Ashburner et al., 2000). Terms for biological processes
related to inflammation dominate in the annotation of the
probe sets defining positive directions of both the first and
second CA axes (Figure 1). In contrast, the term ‘‘cell cycle’’
was the only term found overrepresented in the annotation of
the probe sets defining the negative directions of the CA axes.
The lists of probe sets defining the four ends of the two axes
were also analyzed for overrepresentation of potential
transcription factor-binding sites in the promoters for
the genes interrogated by the probe sets. Overrepresentation
was only found in the promoters of the genes interrogated
by probe sets defining the positive direction of the first CA
axis. Potential binding sites for signal transducers and
activator of transcription (STAT), activator protein 2g (AP-
2g) and small/mothers against decepentaplegic (SMAD) trans-
cription factors were found overrepresented (see Materials
and Methods for details). It is therefore also noteworthy that
probe sets for the STAT1 and the JAK3 kinase reported
increased expression in the late time-point patient samples
(Figure 2 and Table 1). STAT1 was also reported to display
increased expression after hapten application in a recent
DNA microarray-based study of CHS in the rat (Hartmann
et al., 2006).
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Figure 2. Hierarchical clustering of genes involved in the elicitation of ACD. Hierarchical clustering of the 74 probe sets that were significantly differentially
expressed in at least one time point from the patient dataset, as determined by ANOVA. In the cluster diagram, each row represents a probe set and each column
represents a biopsy. The number written immediately after the letter (P for patients) refers to the person and the number after the underscore refers to the time
point. For example, P7_7 is data from patient no. 7 from the 7-hour time point. The colours indicate the experession level: red highest, green lowest.
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Table 1. Genes significantly up- and downregulated during the elicitation of ACD
Affymetrix Expression intensity
1,2
Gene symbol Probe set ID 0 h 7 h 48 h 96 h
Immune response
GZMB 210164_at 2173 1772 1827104 3737138
SELE 206211_at 3877 41720 4477195 6547177
RGS1 216834_at 2771 971 74739 206788
LTB 207339_s_at 209727 112715 8657335 1,2007288
CCR7 206337_at 4473 1971 94739 245774
CCL19 210072_at 1,3767221 377741 3,64671,314 3,6167689
TRBV19 210915_x_at 110715 81715 310748 4767100
TRBV19 213193_x_at 204720 163722 562796 8637181
CD3D 213539_at 150721 116713 3557104 5457109
GBP1 202270_at 164715 9576 302775 5757156
IL2RG 204116_at 102715 6976 279758 312771
GBP1 202269_x_at 210731 15575 4347115 6937120
IL32 203828_s_at 128714 92718 316774 391780
IFI30 201422_at 559739 394726 1,0577386 1,5337101
PSMB10 202659_at 192712 156723 321760 433726
LILRB2 207697_x_at 7577 6074 99720 149714
PSMB8 209040_s_at 284721 263713 414755 485721
PSME1 200814_at 905730 827717 1,172788 1,236750
LILRA2 211100_x_at 4273 3872 4174 5371
Cell mobility/cell adhesion
SELL 204563_at 2675 1772 138768 3477124
PARP9 223220_s_at 158713 10779 283766 415778
CORO1A 209083_at 178725 151723 4577120 592791
ARPC1B 201954_at 632740 526738 1,0577301 1,296779
RAB31 217764_s_at 369714 383710 565743 678750
Intracellular signaling/signal transduction
CXCR4 217028_at 9473 5175 218777 7637317
JAK3 227677_at 7279 4972 3057154 3897124
IL27RA 222062_at 3877 1872 91731 111726
CD3Z 210031_at 3472 2973 100733 144739
CXCR4 209201_x_at 5177 4072 93719 227756
STAT1 M97935_3_at 423753 280720 5727105 9107192
ECOP 208091_s_at 376720 374714 575760 610738
IFNAR2 204785_x_at 7773 8375 10172 11677
P2RY10 1553856_s_at 1571 1571 2772 3073
PGRMC23 201701_s_at 337713 322720 175712 189720
TSC1 209390_at 17476 19978 162710 13176
Actin binding
COTL1 224583_at 220752 143721 369787 539748
TMSB10 217733_s_at 5,7017368 5,4777248 7,7757777 9,2287640
TPM3 222976_s_at 2,100783 1,865717 2,7617438 3,3537119
FGD4 230559_x_at 1271 1071 870 870
Cellular metabolism
IRF1 202531_at 111710 9976 240749 302729
WARS 200628_s_at 141710 12375 293766 319727
Table 1 continued on following page
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Probe sets defining the elicitation of ACD
One important conclusion from the analysis of both control
and patient samples was that there are no signs of genes that
are upregulated in the control subjects as a result of the patch
test. The gene expression changes occurring in nickel-allergic
subjects during the nickel patch test therefore only reflects the
Table 1. continued
Affymetrix Expression intensity
1,2
Gene symbol Probe set ID 0 h 7 h 48 h 96 h
ODC1 200790_at 379733 346723 7137146 830782
LAP3 217933_s_at 655744 525722 9797227 1,2517135
UBE2L6 201649_at 280722 22676 33878 491753
PIM2 204269_at 4871 4674 75713 7874
ADSL 210250_x_at 32174 293710 422763 501723
PRPS1 209440_at 222714 206710 303729 334715
ALOX5 236199_at 2671 2971 3372 4071
IFT122 241336_at 6375 6573 4973 3574
CAND2 213547_at 4774 4472 3571 3372
GATAD1 214718_at 231710 21479 157724 12779
USP31 227256_at 15278 143711 171713 9475
Miscellaneous
ARHGAP9 232543_x_at 5373 4674 120736 128717
S100A7 205916_at 3,1057385 237757 3,2237858 3,77371,189
FKBP1A 210187_at 2471 2072 3575 6079
CLIC1 208659_at 1,524791 1,508760 1,9617251 2,260760
HMGN4 202579_x_at 475725 437721 616755 638725
SCUBE2 219197_s_at 133714 11577 81714 6378
HIST2H2BE 202708_s_at 10973 94711 6976 5874
RICS 242196_at 2771 2472 1772 1670
NRXN1 209914_s_at 4572 4972 3571 3172
Unknown function
PRG1 201859_at 618773 380719 1,2907449 1,9947252
— 238725_at 5976 5975 210765 232752
CXorf9 204923_at 5977 4372 158747 195726
PRG1 201858_s_at 350721 286721 8487339 1,1987128
KIAA0746 212311_at 3072 3073 75712 7279
— 229221_at 3672 3172 57718 7678
FLJ20647 218802_at 15575 15776 204741 28378
C6orf129 225723_at 82710 7074 106719 12374
KIAA1189 231911_at 1171 1070 1170 1571
— 224343_x_at 1270 1270 1771 1871
— 230991_at 1271 1370 1471 1770
FRMD4A 1560031_at 27276 305737 204723 122710
FRMD4A 208476_s_at 16876 219721 135715 7977
GRTP1 229377_at 139710 124711 88720 5875
TANC 225308_s_at 760725 722734 470768 427724
— 236766_at 5772 6275 3775 3172
KIAA1704 226429_at 16078 165712 93712 9176
KIAA1002 203831_at 245712 249710 202719 18075
ACD, allergic contact dermatitis.
1Classification based on annotation and terms defined by the Gene Ontology Consortium
2Mean7SE.
3Probe sets reporting decreased expression measures at later time points compared with the 0 h time point are typed in bold.
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elicitation of ACD and these changes can accordingly be
studied in isolation. A one-way ANOVA of the patient data
resulted in the identification of 74 probe sets, which yielded a
differential expression measure over time. Cluster analysis
revealed that the majority of the probe sets reported an
increased expression measure at time point 48 and 96 hours
compared to time point 0 and 7 hours (Figure 2). Only the
gene expression profile from one sample (the 48 hours biopsy
from patient no. 7), did not fit into the described pattern in
that it clustered together with the early time-point samples
(Figure 2).
In Table 1, the expression levels of all 74 probe sets are
given. The gene with the greatest increase in expression
(16-fold) in the 48- and 96-hour biopsies compared to the
0- and 7-h our biopsies was granzyme B. Granzyme B is an
enzyme necessary for cell lysis in cell-mediated immune
responses (Trapani, 2001). Granzyme B was also found
upregulated in the DNA microarray study of CHS in the
rat (Hartmann et al., 2006). The gene expression profiles of
the 0-hour time point were also compared to the 7-hour
time point using a Student’s t-test, but no probe sets were
found to report a differential expression measure when
using the predefined significance level (false discovery rate
o5%). Thus, only minor changes have been induced in the
skin transcriptome of an allergic subject 7 hours after
exposure to allergen. CCL19 was the only chemokine found
to be upregulated (Table 2) using the chosen significance
level and we therefore specifically investigated the expres-
sion levels for the CCL2, CCL5, CCL17, CCL18, CCL19,
CXCL9, and CXCL10, which have previously been demon-
strated to be upregulated in the elicitation of ACD by the use
of in situ hybridization (Goebeler et al., 2001). All of these
chemokines were found to be upregulated in the late time
points compared to the early time points by at least twofold in
our study with a P-value below 0.01 for the ANOVA.
However, the q-value assigned to adjust for multiple tests
were above 0.05 and these chemokines were therefore not
represented in Table 1.
Table 2. Quantitative real-time RT-PCR generally confirms the differential expression for the selected genes
Expression intensity array versus real-time RT-PCR1,2
0 h 7 h 48 h 96h
Gene symbol Array RT Array RT Array RT Array RT
SELE P4 3877 19,58472,765 41720 56,760717,671 4477195 325,1117108,829 6547177 122,641741,412
C 2976 25,554 37713 30,044710,926 3174 25,196 2877 19,662
IFI30 P 559739 398,517747,500 394726 359,081726,951 1,0577386 611,1607154,615 1,5337101 834,8437104,921
C 5187118 317,411 358725 272,724736,191 394745 292,915 454797 350,157
IL32 P 128714 2,758,4157
599,274
92718 2,443,4217
365,419
316774 5,123,99371,183,530 391780 7,202,65971,870,882
C 131717 2,847,666 103722 2,357,1677777,131 117717 1,965,779 129732 2,131,492
CD3D P 150721 50,42075,519 116713 51,59976,899 3557104 389,0617220,021 5457109 161,691741,981
C 142752 41,790 97719 45,264720,657 108722 36,131 128737 30,156
CCL19 P 1,3767221 642,3717
140,322
377741 265,254722,906 3,64671,314 1,537,4117
480,788
3,6167689 1,509,2067
294,681
C 1,1107256 480,505 4187134 244,181782,875 613796 269,448 4737164 304,895
PSMB83 P 284721 147,2097
59,391
263713 133,137739,631 414755 99,863735,670 485721 84,617721,541
C 269772 36,858 264714 39,53873,030 308717 37,521 277744 40,041
TMSB10 P 5,7017368 3,032,1217
4,57,181
5,7767248 2,633,2317
97,023
7,7757777 3,417,1097
3,31,036
9,2287
640
3,539,3197
421,239
C 6,7647398 3,170,290 5,6257293 2,601,6567
320,173
5,9307204 2,635,176 6,7037607 3,598,768
BTC3 P 46714 4,7977834 6179 6,80272,016 2779 4,0897882 2478 2,4137454
C 132724 1,712 179742 1,8947208 148716 1,152 216747 1,676
CNTN3 P 4074 3967103 4474 368739 2775 250771 2674 134720
C 148744 1,346 139728 7627201 121730 810 152742 730
RT, reverse transcription.
1Mean7SE.
2For some of the control samples the SE could not be calculated because too few samples were available.
3These genes do not show the expression pattern predicted by the microarray experiment.
4P: patients, C: controls.
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CCL19 is expressed in deep dermal cells in the late phase of
ACD elicitation
To validate the DNA microarray data, the expression of nine
genes interrogated by probe sets with differential expression
measures was quantified by real-time reverse transcription
(RT)-PCR (Table 2). Only two of the genes did not show the
expression pattern predicted by the corresponding probe set
expression measure. Interestingly, the quantitative real-time
RT-PCR analysis also confirmed the upregulation of CCL19
and we investigated if the upregulation of CCL19 might also
be confirmed at the protein level using immunocytochem-
istry. For this purpose a separate biopsy series was obtained
from one ACD patient and from one control subject, both of
whom were not included in the DNA microarray study. As
seen in Figure 3(a–c), weak staining for CCL19 was seen
in the basal and suprabasal epidermal cells at the 0-, 7-, and
96-hour time points in the skin from nickel-allergic subjects.
The skin from the control subjects showed the same weak
epidermal staining (not shown). At the 96-hour time point,
scattered points of strong staining were in addition seen in the
deeper part of the dermis from the nickel-allergic subject
(Figure 3c), but not in the skin from the control subject (not
shown). At a higher magnification (Figure 3d), it could be
seen that the staining appeared cloudy and diffuse around
strongly staining cells. Thus, the staining suggests that CCL19
is released from CCL19-positive cells displaying an irregular
morphology. The mRNA for CCR7 was also found to be
upregulated at the 48- and 96-hour time points (Table 1).
Using a CCR7 antibody, staining was seen in cells scattered
in and beneath the epidermis (Figure 3e). This CCR7 staining
was seen both in the skin from a control subject and in the
skin from the patient at all time points (not shown).
In addition, CCR7-positive cells were found scattered deeper
in the dermis and in some cases CCR7-positive cells were
found in small clusters. These clusters were most easily
recognized in the 96-hour patient sample (Figure 3f), but the
limited amount of material did not permit a quantitative
analysis of the distribution. The 48-hour time-point biopsy
from the same series (Figure 3) was divided into fractions by
serial sectioning. This allowed the extraction of RNA from
fractions representing different regions of the biopsy. Three
fractions were produced (Figure 4). The epidermal fraction
(fraction 1), the upper dermal fraction (fraction 2), and the
deep dermal fraction (fraction 3). Quantitative real-time RT-
PCR analysis showed that both the CCL19 and the CCR7
transcripts were only detectable in the deep dermal fraction,
whereas control transcripts were detectable in all fractions
with highest expression level in either the deep dermal
fraction (SELE) or in the epidermal fraction (S100A7),
respectively. CCL19 mRNA was, however, detectable by
quantitative real-time RT-PCR analysis in the 0 hour biopsies
(Table 2), where CCL19 immunostaining was only found in
the basal part of the epidermis. The failure to detect CCL19
mRNA by quantitative real-time RT-PCR in the epidermal
fraction (Figure 4), therefore, probably reflects the very low
amounts of RNA recovered from the tissue sections. Thus
only the dermal fractions from the 48-hour biopsy contain
sufficient amounts of CCL19 mRNA to allow detection by
quantitative real-time RT-PCR. Combined immunocytochem-
ical and quantitative real-time RT-PCR analyses of the biopsy
fractions therefore strongly suggest that CCL19 expression is
highly upregulated in cells located in the deeper part of the
dermis during elicitation of ACD and that this upregulation is
accompanied by increased expression of mRNA for CCR7 in
the dermis.
DISCUSSION
This study provides early evidence of the global gene
expression in the human skin during the elicitation of ACD.
Genome-wide gene expression analysis has previously been
carried out in nickel-exposed peripheral mononuclear blood
cells from nickel allergic subjects (Hansen et al., 2005) and in
cultured DCs exposed to dinitrobenzenesulfonic acid (Ryan
et al., 2004). Comparisons of the gene expression changes in
the skin revealed in this study with those previous reports
only resulted in the identification of the chemokine receptor
CXCR4, which was also found upregulated in allergen-
stimulated DCs (Ryan et al., 2004). The gene expression time
a b
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Figure 3. Expression of CCL19 and CCR7 in nickel-exposed skin from
allergic subjects. Punch biopsies of 4 mm were taken from a nickel-allergic
subject at the time points 0, 7, 48, and 96 hours following the exposure of skin
to nickel during a patch test. The biopsies were taken from the skin beneath
the patch test. The biopsies from the time points (a) 0 hour, (b) 7 hours,
and (c and d) 96 hours after nickel exposure were analyzed with a CCL19
antibody. (c) At the 96-hour time-point staining deep dermal structures are
visible. (d) At a higher magnification the staining appears cloudy around cells
with an irregular morphology. (e) The expression of CCR7 was analyzed in a
biopsy from a control subject and (f) from an allergic subject 96 hours after
nickel exposure. The staining was found in cells scattered in and beneath (e)
the epidermis and in the dermis. In some areas the CCR7-positive cells were
arranged in clusters in (f) the deep dermis. Bar¼250 mm.
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course in the skin during elicitation of ACD is therefore very
different than the expression changes observed in mono-
nuclear cells or in DCs isolated from peripheral blood.
Compared with a study of CHS in the rat (Hartmann et al.,
2006), transcripts for STAT1, IRF1, PSMB8, and GRZMB were
predicted to be upregulated in both studies.
Potential and unexpected role of CCL19 during the elicitation of
ACD
CCL19 and CCL21 are required to elicit an inflammatory
response in murine CHS (for reviews see Wang et al., 2003;
Ebert et al., 2005). The dogma is, however, that it is the
trafficking of T lymphocytes and DCs to the LNs during
the sensitization phase, which is defective in these mice.
CCL19 and CCL21 are generally referred to as homeostatic
chemokines that are constitutively expressed in LNs (Ebert
et al., 2005). Our finding of a highly significant upregu-
lated expression of CCL19 in dermal cells during elicita-
tion of ACD suggests that this chemokine and its receptor
might also be involved in the elicitation phase. An interesting
hypothesis might be that dermally expressed CCL19
recruits and colocalizes CCR7-positive DCs with CCR7-
positive T cells directly in the dermis of a sensitized
subject. Recently it has been reported that the other CCR7
ligand, CCL21, is expressed in the dermis after irritant
exposure and also during elicitation of ACD (Eberhard
et al., 2004; Serra et al., 2004). In our gene expression
analysis, the CCL21 probe set reported an approxi-
mately twofold higher expression measure at the 48-hour
time point than at the 0 hour time point with a P-value of
0.03. Thus, although this P-value did not pass the correction
for multiple tests in our DNA microarray experiment, the
finding is interesting, supports the upregulation of CCL21
during ACD and might therefore suggest that CCL19 and
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Figure 4. CCL19 mRNA is expressed in the deep dermis beneath the area of nickel exposure during elicitation of ACD. A 4 mm punch biopsy from the 48-hour
time point of the time-series experiment shown in Figure 3 was sectioned in parallel to the epidermal surface. The sections were pooled in fractions and RNA
extracted. Every tenth section was retained for haematoxylin/eosin staining. The micrograph (bar¼ 100mm) on the left is a section from the 96-hour time point.
The micrographs (bar¼ 100mm) on the right are haematoxylin/eosin-stained sections of the 48-hour biopsy (Figure 3 legend) corresponding to section 10
(700mm from the surface), section 20 (140mm from the surface), and section 40 (280 mm from the surface). Sections 1–9 were pooled as fraction 1 (epidermis
fraction), sections 11–20 were pooled as fraction 2 (upper dermis fraction), and sections 31–100 were pooled as fraction 3 (lower dermis fraction). RNA was
extracted and converted into cDNA. Copy numbers of the indicated transcripts were measured in the fractions by quantitative real-time PCR. The transcript for
glyceraldehyde 3-phosphate dehydrogenase was used for normalization. The CCL19 and CCR7 transcripts could not be detected in the fractions 1 and 2
(indicated by asterisks), but were detectable in fraction 3 corresponding to the lower dermis fraction.
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CCL21 together cooperate during elicitation of ACD by
recruiting CCR7-positive cells to the dermis at the site of
hapten exposure.
Functional interpretation of transcriptome changes during
elicitation of ACD
The promoter cis-element overrepresentation analysis sug-
gests that STAT and SMAD transcription factors might be
involved in mediating the transcriptome changes observed
during elicitation of ACD. STATs are downstream of g-
interferon signaling that promotes inflammation (for a review
see O’neill, 2006). SMADs are downstream of transforming
growth factor-b signals that dampen the inflammatory
response (for a review see Hanada and Yoshimura, 2002).
A straightforward interpretation is that the opposing signaling
of the two cytokines is reflected in the late time-point
transcriptome data. Whereas the involvement of interferon-g
signaling and the downstream STAT transcription factors was
anticipated from the current knowledge (Wang et al., 2003),
the overrepresentation of SMAD cis-elements in the promo-
ters of genes involved in the elicitation of ACD and the
potential involvement of transforming growth factor-b and
SMAD signaling was unexpected and worth investigating in
future studies.
MATERIALS AND METHODS
Subjects
For the microarray study, seven nickel-allergic patients and five
nonallergic controls were recruited. In addition, one nickel-allergic
patient and one healthy control were recruited for the immuno-
cytochemistry study. All participants were women and all patients
had at least a 2þ reaction to 5% nickel sulfate at the time of
diagnosis. The age of the patients ranged from 33 to 49 (mean age
40) and the age of the controls ranged from 31 to 55 (mean age 43).
None of the participants used any immunosuppressive medications
during the time of the study.
The design and conduct of the skin sampling was in agreement
with the declaration of Helsinki Principles. All subjects gave written
and informed consent. The study was approved by the Local Ethics
Committee.
Allergen exposure and skin biopsies
All patch tests were applied on the upper nates. The patch tests were
performed using 5% nickel sulfate in pet (NiSO4; Sigma-Aldrich,
Broendby, Denmark). The allergen was applied using 8 mm Finn
Chamberss (Epitest, Tuusula, Finland) with Scanpors tape (Norges-
plaster, Vennesla, Norway).
All participants were exposed to three patch tests with 5% nickel
sulfate: (i) the first patch test was exposed for 7 hours and a skin
biopsy was taken immediately after removing the patch test; (ii) the
second patch test was exposed for 48 hours immediately followed by
a skin biopsy; and (iii) the third patch test was exposed for 48 hours
and the skin biopsy was taken 48 hours after removing the patch test
(the 96-h biopsy). In addition, all participants were exposed to an
empty patch test exposed for 48 hours followed by a skin biopsy. As
a result, we obtained four skin biopsies from each participant
corresponding to different time points during the development of
ACD: 0, 7, 48, and 96 hours. Before taking the skin biopsies (4 mm
punch biopsies), the skin was frozen using a liquid nitrogen spray to
inhibit RNA degradation. The skin biopsy specimens were immedi-
ately placed in liquid nitrogen and were later transferred to a 801C
freezer.
RNA extraction
For RNA extraction, the skin biopsies were placed in a mortar
filled with liquid nitrogen and ground mechanically using a pestal.
The tissue was transferred to a lysis buffer and RNA was extracted
using the RNase Lipid Tissue Kit (Qiagen, Valencia, CA). The
amount and quality of the extracted RNA was evaluated using a lab-
on-a-chip Bioanalyzer (Agilent Technologies, Santa Clara, CA).
Based on the quality of the RNA, a total of 16 control samples and 18
patient samples were found suitable for the microarray experiment,
resulting in 3–6 samples per time point for both the patients and the
controls. After probe generation for microarray hybridization,
sufficient amounts of RNA remained for validation by real-time
quantitative RT-PCR from nine control samples and 23 patient
samples.
DNA microarrays
Generation of cDNA, biotin-labeled cRNA and GeneChip hybridi-
zation was performed by the RH Microarray Centre at Rigshospitalet
(Copenhagen, Denmark) as described previously (Hansen et al.,
2005). The calculated expression measures and the original data
(CEL files) have been submitted to the Gene Expression Omnibus
under the accession number GSE6281.
Real-time RT-PCR
Primers for amplification of fragments (between 150 and 250 bp) of
the transcripts indicated in Table 2 were chosen from the
PrimerBank resource (Wang and Seed, 2003). All amplified PCR
products were sequenced to verify the expected identity and melting
curves were routinely checked to rule out the amplification of
unrelated fragments during quantitative real-time RT-PCR. For the
results reported in Table 2 (analysis of whole biopsies), 50 ng of
reverse-transcribed total RNA was used as template. For the results
reported in Figure 4 (analysis of biopsy fractions), 50 pg of reverse-
transcribed total RNA was used as template. The PCR reactions were
run using the LightCycler PCR system (Roche, Manheim, Germany).
All procedures for the preparation of PCR products for calibration,
PCR sequence verification, cDNA synthesis, real-time RT-PCR
amplification, and copy number quantification have been described
previously (Hansen et al., 2005; Csillag et al., 2007b). The copy
numbers for the glyceraldehyde 3-phosphate dehydrogenase tran-
script were used for normalization between samples.
Immunocytochemistry
Frozen sections of 7 mm were prepared from skin biopsies. The
sections were fixed in acetone (41C) for 10 minutes. The sections
were incubated for 30 minutes in blocking buffer (50 mM Tris–HCl
(pH 7.4), 150 mM NaCl, 0.5 % ovalbumin, 0.1% gelatine, 0.2%
teleostean gelatine, and 0.05 % Tween-20) and incubated (41C) with
a 1:40 dilution of a CCL19 mouse monoclonal antibody (catalog
number MAB361, R&D Systems, Abingdon, UK) or CCR7 antibody
(catalog number 14-9977-80, eBioscience, San Diego, CA) in
blocking buffer overnight. The sections were washed three times
for 10 minutes each in blocking buffer and incubated for 30 minutes
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at room temperature with a 1:100 dilution of an Alexa-488-
conjugated goat anti-mouse antibody (Invitrogen, Carlsbad, CA).
After three washes in PBS, the sections were mounted for
fluorescence microscopy using DAPI containing Prolong Gold
antifade (Invitrogen). One 48-hour patient biopsy was fractionated
by serial sectioning in parallel to the epidermis. Details about the
fraction collection are given in the legend to Figure 4.
Data analysis
In general, the statistical computations were done using the R
environment for statistical computing (for an introduction to R, see
Dalgaard, 2002). Summarization of probe level data from the
scanned GeneChips into single normalized gene expression mea-
sures for each probe set was performed using the robust multiarray
analysis procedure with quantile normalization and robust multi-
array analysis background correction (Irizarry et al., 2003). A total of
eight groups were defined (0, 7, 48, and 96 hours for patients and
control subjects) and used in the one-way ANOVA. To deal with
multiple tests, a false discovery rate (Storey and Tibshirani, 2003)
strategy was applied. The set of P-values obtained after performing
ANOVA for each probe set were used to calculate q-values, and
probe sets with q-values below 0.0001 were considered significant.
CA was performed using the Made4 library (Culhane et al., 2005) for
R. The genes contributing the most to the CA axes were extracted
from the CA loading matrix as the loadings with values 41 or o 1,
respectively, for the CA axes. Probe sets with loading values below
1 defined the negative direction of each axis and probe sets with a
loading value 41 defined the positive direction of each CA axis.
This criterion yielded between 108 and 145 probe sets defining the
axes. For each axis the list probe sets with positive loadings and the
list of probe sets with negative loadings were analyzed for
overrepresented terms for biological processes using the graphical
GoSurfer functional annotation analysis tool (Zhong et al., 2004).
In addition, the promoters for the genes represented by these probe
sets were analyzed for overrepresentation of potential promoter
cis-elements using PRIMO software (Stegmann et al., 2006) and a set
of 65 position weight matrices defining binding sites for vertebrate
transcription factors (Stegmann et al., 2006). The obtained P-values
were corrected for multiple testing by the Bonferroni procedure
(Armitage et al., 2002). Three matrices detected overrepresented
(M00497, STAT3, 31 promoters with hits and 73 promoters without
hits, P¼ 0.03; M00470, AP-2g, 31 promoters with hits, 73 promoters
without hits, P¼ 0.003; M00792, SMAD, 28 promoters with hits, 76
promoters without hits, P¼ 0.0003) cis-elements in the promoters
defined by the list of probe sets defining the positive direction of the
first CA axis. The consensus sequences for the binding sites were as
follows: M00497, 50-G/C G/C A/C TTCC C/G-30; M00470, 50-GCC
C/T NN GG C/G-30; M00792, 50-AGACNCC-30. The consensus
binding sequences for STAT3 and STAT1 are very similar (Park and
Schindler, 1998) and the M00497 matrix is not able to distinguish
between the two different STAT transcription factors.
To analyze the allergic response in more detail, the patient data
were also investigated separately. ANOVA was conducted followed
by calculations of q-values as described above, except that a
significance level of 0.05 for the q-value was chosen.
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